Mistry Jayna J, Hellmich Charlotte, Lambert Amelia, Moore Jamie A, Jibril Aisha, Collins Angela, Bowles Kristian M, Rushworth Stuart A
Norwich Medical School, University of East Anglia, Norwich Research Park, NR4 7UQ, Norwich, UK.
Earlham Institute, Norwich Research Park, NR4 7UH, Norwich, UK.
Biomark Res. 2021 May 13;9(1):35. doi: 10.1186/s40364-021-00291-y.
Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.
尽管近期治疗方面取得了进展，但急性髓系白血病（AML）仍然是一种无法治愈的恶性肿瘤。最近出现了一些用于治疗AML的新疗法，这些疗法靶向BCL-2或膜受体CD38。在此，我们表明，维奈托克（Venetoclax）和达雷妥尤单抗（Daratumumab）联合治疗在体外和体内均导致肿瘤进展较慢且白血病生长减少。这些数据为维奈托克和达雷妥尤单抗联合治疗AML的临床评估提供了证据。
